← All trials
NCT04855747
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 30, 2021
- Primary completion
- Jun 30, 2022
- Completion date
- Jun 30, 2022
- First posted
- Apr 22, 2021
- Last posted
- Jul 27, 2021
- Enrollment
- 400
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Relmada Therapeutics, Inc.Lead sponsor
- Relmada Therapeutics, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.